Interaction of Radiopharmaceuticals with Somatostatin Receptor 2 Revealed by Molecular Dynamics Simulations

Area of Science:

• Biochemistry
• Molecular Biology
• Radiopharmaceutical Chemistry

Background:

• Somatostatin receptor 2 (SSTR2) is overexpressed in neuroendocrine tumors, making it a key target for drug development.
• Radiopharmaceuticals, combining somatostatin analogues with radionuclides, are used for diagnosing and treating these tumors.
• A detailed molecular understanding of radiopharmaceutical-receptor interactions is lacking.

Purpose of the Study:

• To analyze the molecular dynamics and interactions of SSTR2 with six clinically relevant radiopharmaceuticals.
• To elucidate the roles of the peptide, chelator, and radionuclide components in receptor binding.
• To provide insights for designing novel, potent SSTR2-targeting ligands.

Main Methods:

• Molecular dynamics simulations were employed.
• Recently determined SSTR2 structures were utilized.
• Analysis focused on binding modes and interaction patterns.

Main Results:

• Distinct binding modes and interaction patterns were identified for the six radiopharmaceutical compounds.
• The influence of different compound portions (peptide, chelator, radionuclide) on SSTR2 interaction was explored.
• Detailed molecular interactions critical for radiopharmaceutical recognition were unveiled.

Conclusions:

• This study provides a microscopic, well-founded analysis of radiopharmaceutical interactions with SSTR2.
• The findings offer guidelines for the rational design of new, potent SSTR2-targeting ligands.
• Understanding these interactions is crucial for advancing neuroendocrine tumor diagnostics and therapeutics.